Circulating adiponectin and endometrial cancer risk

Luigino Dal Maso, Livia S A Augustin, Aspasia Karalis, Renato Talamini, Silvia Franceschi, Dimitrios Trichopoulos, Christos S. Mantzoros, Carlo La Vecchia

Research output: Contribution to journalArticlepeer-review


Circulating levels of adiponectin, a hormone with insulin-sensitizing properties, are decreased in conditions related to obesity and hyperinsulinemia, which are recognized risk factors for endometrial cancer. Eighty-seven cases with incident, histologically confirmed endometrial cancer and 132 controls admitted for acute, nonneoplastic diseases were interviewed in northeastern Italy between 1999 and 2002, and blood samples were collected. Levels of adiponectin were evaluated in samples by means of a RIA. An inverse association with endometrial cancer risk emerged for plasma adiponectin levels [odds ratio (OR), 0.42; 95% confidence interval, 0.19-0.94] when comparing the highest vs. the lowest tertiles. Similar results emerged for serum adiponectin (OR, 0.30; 95% confidence interval, 0.14-0.68). The association was stronger in pre- than in postmenopausal women, but no significant heterogeneity was observed across strata of body mass index (BMI) or parity. BMI and adiponectin showed independent effects on the risk of endometrial cancer according to a multiplicative model (OR, 6.45 in the highest level of BMI and in the lowest one of adiponectin).

Original languageEnglish
Pages (from-to)1160-1163
Number of pages4
JournalJournal of Clinical Endocrinology and Metabolism
Issue number3
Publication statusPublished - Mar 2004

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Circulating adiponectin and endometrial cancer risk'. Together they form a unique fingerprint.

Cite this